Novo Nordisk (NVO) rated Buy as oral Wegovy lifts GLP-1 sales, expands obesity market and boosts 2026 guidance.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (othe… [678 chars]
Source: Seeking Alpha | Published: 2026-07-04T15:04:56Z
Credit: Seeking Alpha
